Q2 EPS Estimates for Annovis Bio Raised by HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS) – Research analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for Annovis Bio in a research report issued on Monday, June 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Annovis Bio’s Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.45) EPS and FY2025 earnings at ($1.52) EPS.

Separately, Canaccord Genuity Group cut their target price on shares of Annovis Bio from $26.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $30.25.

Annovis Bio Stock Up 5.4%

NYSE:ANVS opened at $2.95 on Wednesday. The firm’s fifty day simple moving average is $1.86 and its 200 day simple moving average is $3.08. The stock has a market cap of $57.48 million, a P/E ratio of -0.66 and a beta of 1.62. Annovis Bio has a twelve month low of $1.11 and a twelve month high of $17.88.

Annovis Bio (NYSE:ANVS) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15.

Institutional Investors Weigh In On Annovis Bio

Several hedge funds have recently bought and sold shares of ANVS. Lokken Investment Group LLC grew its stake in shares of Annovis Bio by 49.0% in the 4th quarter. Lokken Investment Group LLC now owns 18,235 shares of the company’s stock worth $92,000 after buying an additional 6,000 shares during the last quarter. Northern Trust Corp grew its stake in shares of Annovis Bio by 49.4% in the 4th quarter. Northern Trust Corp now owns 32,780 shares of the company’s stock worth $165,000 after buying an additional 10,846 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Annovis Bio in the 4th quarter worth approximately $55,000. XTX Topco Ltd purchased a new stake in shares of Annovis Bio in the fourth quarter worth $59,000. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Annovis Bio in the fourth quarter worth $65,000. Institutional investors own 15.83% of the company’s stock.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.